<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137952">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016781</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN1102</org_study_id>
    <secondary_id>2U10HL069294-11</secondary_id>
    <nct_id>NCT02016781</nct_id>
  </id_info>
  <brief_title>Allo vs. Hypomethylating/Best Supportive Care in MDS (Blood and Marrow Transplant Clinical Trials Network #1102)</brief_title>
  <official_title>A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 w/Intermediate-2 &amp; High Risk Myelodysplastic Syndrome Blood and Marrow Transplant Clinical Trials Network #1102)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a multicenter trial, with biological assignment to one of two
      study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell
      transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:  MDS is a clonal disorder of hematopoietic precursors and stem cells, which may
      evolve to a terminal phase resembling acute leukemia.  A subject of clinical urgency for
      researchers, clinicians, patients, and health care underwriters such as Medicare, is the
      role of allogeneic hematopoietic cell transplantation (alloHCT) in the treatment of older
      patients with higher risk myelodysplastic syndromes (MDS).  The use of reduced intensity
      conditioning (RIC) regimens has extended HCT to the care of older patients with acute
      myelogenous leukemia (AML) and lymphoma and a number of retrospective and phase II trials
      for patients with MDS now show the curative potential of RIC alloHCT in selected patients.

      This protocol is designed evaluate the relative benefits of RIC alloHCT compared to
      non-transplant therapies focusing on overall survival.   This will be done by having
      patients biologically assigned to the alloHCT arm or the hypomethylating therapy/best
      supportive care arm and following them for survival at 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Overall survival probabilities</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival (LFS)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL measures</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>MDS</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Cell Transplant</intervention_name>
    <arm_group_label>MDS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypomethylating Therapy or Best Supportive Care</intervention_name>
    <arm_group_label>MDS</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patient peripheral blood and buccal swab samples will be collected at enrollment.
      Peripheral blood (and bone marrow samples if available) will also be collected from patients
      assigned to the HCT arm who experience relapse at the time of relapse and stored to support
      future research studies.  If available, bone marrow will be collected pre-transplant for the
      patients assigned to the HCT arm.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        De novo MDS patient between the ages of 50 and 75 years with no prior history of allo HCT.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the following criteria will be eligible for entry into this
             study:

               1. Patients with de novo MDS who have, or have previously had, Intermediate-2 or
                  High risk disease as determined by the International Prognostic Scoring System
                  (IPSS).  Current Intermediate-2 or High risk disease is NOT a requirement.

               2. Patients must have fewer than 20% marrow blasts at the time (within 30 days) of
                  registration and consent.

               3. Patients may have received prior therapy for the treatment of MDS, including but
                  not limited to: growth factor, transfusion support, immunomodulatory (IMID)
                  therapy, DNA hypomethylating therapy or cytotoxic chemotherapy prior to trial
                  registration.

               4. Age 50.0-75.0 years.

               5. Karnofsky performance status &gt; 70 or Eastern Cooperative Oncology Group (ECOG) â‰¤
                  1 (see comparison scale in Appendix D).

               6. Patients are eligible if no formal unrelated donor search has been activated
                  prior to enrollment.  Patients who have started a sibling donor search or who
                  have found a matched sibling donor are eligible.

               7. Patients and physicians must be willing to comply with treatment assignment:

                    1. No intent to proceed with alloHCT using donor sources not specified in this
                       protocol, including Human leukocyte antigen (HLA)-mismatched related or
                       unrelated donors &lt; 6/6 HLA related matched or &lt; 8/8 HLA unrelated matched)
                       or umbilical cord blood unit(s).

                    2. No intent to use myeloablative conditioning regimens.

                    3. Intent to proceed with RIC alloHCT if a matched sibling or matched
                       unrelated donor is identified.  There is no requirement as to the timing of
                       the transplantation.

               8. Patients must be considered to be suitable RIC alloHCT candidates at the time of
                  enrollment based on medical history, physical examination and available
                  laboratory tests.  Specific testing for organ function is not required for
                  eligibility but, if available, these tests should be used to judge eligibility.

               9. Signed informed consent

        Exclusion Criteria:

          -  Patients with the following will be ineligible for registration onto this study:

               1. Therapy-related MDS

               2. Current or prior diagnosis of AML

               3. Uncontrolled bacterial, viral or fungal infection

               4. Concurrent malignancy other than superficial squamous cell or basal cell
                  carcinoma of the skin

               5. Prior autologous or allogeneic HCT

               6. Human Immunodeficiency Virus (HIV) infection

               7. Fertile patients unwilling to use contraceptive techniques

               8. Patients with psychosocial conditions that would prevent study compliance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda Johnson, MD, MS</last_name>
    <phone>301-251-1161</phone>
    <phone_ext>2834</phone_ext>
    <email>ljohnson@emmes.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryotaro Nakamura, MD</last_name>
      <phone>626-256-4673</phone>
      <email>RNakamura@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Benjamin, MD</last_name>
      <phone>650-723-0822</phone>
      <email>jbenjam@Stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Wingard, MD</last_name>
      <email>john.wingard@medicine.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Artz, MD, MS</last_name>
      <phone>773-834-8980</phone>
      <email>aartz@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph McGuirk, DO</last_name>
      <phone>913-588-9031</phone>
      <email>jmcguirk@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Cutler, MD, MPH</last_name>
      <phone>617-632-5946</phone>
      <email>corey_cutler@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DFCI/MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Bin Chen, MD</last_name>
      <email>Ychen6@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute/BMT</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Voravit Ratanatharathorn, MD</last_name>
      <email>ratanath@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University/Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Westervelt, MD, PhD</last_name>
      <phone>314-454-8306</phone>
      <email>pwestervelt9876@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Shea, MD</last_name>
      <phone>919-966-7746</phone>
      <email>tom_shea@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital BMT Program</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Gerds, MD</last_name>
      <email>gerdsa@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Maziarz</last_name>
      <email>maziarzr@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rammurti Kamble</last_name>
      <email>Kamble@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson CRC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betul Oran, MD</last_name>
      <email>boran@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University MCV Hospitals</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John McCarty, MD</last_name>
      <phone>804-828-4596</phone>
      <email>jmccarty@vcu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctnsp.net</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
